Racial Variations in PSA and PSA Density Among Men With Negative Prostate Biopsies: A Multicenter Comparative Study of Chinese, African American, and Caucasian American Populations.
- 1Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
- 2School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
- 3Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Abstract
Background
Prostate-specific antigen (PSA) and PSA density (PSAD) are widely used for prostate cancer (PCa) screening, but their diagnostic thresholds have not been differentially adjusted for ethnic groups in clinical practice. This multicenter study aimed to establish the distribution of PSA and PSAD in Chinese men without PCa and compare these values with published data from African American (AA) and Caucasian American (CA) men to assess potential racial disparities.Methods
We analyzed 528 biopsy-negative Chinese men from two tertiary centers, comparing their age-adjusted PSA/PSAD with published AA/CA data. Additionally, we compared PSA/PSAD distributions and the proportion of men exceeding the conventional PSA cutoff (4 ng/mL) across racial groups.Results
PSA levels showed a weak but significant positive correlation with age (r = 0.121, p = 0.005), whereas PSAD did not (r = -0.032, p = 0.465). Notably, Chinese men without PCa exhibited significantly higher mean PSA and PSAD than AA and CA men (PSA: 17.28 vs. 7.97 vs. 4.30 ng/mL, p < 0.001; PSAD: 0.28 vs. 0.19 vs. 0.11 ng/mL/mL, p < 0.001). Using a PSA cutoff of 4 ng/mL, the specificity for PCa detection was substantially lower in Chinese men than in AA and CA men at matched sensitivity levels.Conclusions
This study reveals striking racial differences in baseline PSA and PSAD among men without PCa, with Chinese men demonstrating markedly higher values than AA and CA counterparts. These findings challenge the universal application of current PSA thresholds and underscore the need for race-specific adjustments to optimize PCa screening accuracy.
Related
- Comparative Prognostic Value of AFP, PIVKA-II, and GPC-3 in Hepatocellular Carcinoma: A Real-World Multicenter Cohort Study
- Comparative evaluation of the antipyretic and analgesic efficacy and safety of a fast-release paracetamol 650 mg formulation vs. conventional paracetamol formulations in adults with acute febrile or febrile-pain conditions: a multicenter randomized controlled trial
- External Validation of the PACTO Risk Score for Infective Endocarditis in Patients With Coagulase-Negative Staphylococcal Bacteremia: A Multicenter Cohort Study.
- First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
- Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial
BibTeX
@article{xiong2026racial,
title = {{Racial Variations in PSA and PSA Density Among Men With Negative Prostate Biopsies: A Multicenter Comparative Study of Chinese, African American, and Caucasian American Populations.}},
author = {Zhi Xiong and Ping Zhou and Abai Xu and Chaojun Guo and Siwei Xiong and Ping Tang},
journal = {Cancer medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72440},
url = {https://europepmc.org/article/MED/42952419},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Racial Variations in PSA and PSA Density Among Men With Negative Prostate Biopsies: A Multicenter Comparative Study of Chinese, African American, and Caucasian American Populations.
AU - Zhi Xiong
AU - Ping Zhou
AU - Abai Xu
AU - Chaojun Guo
AU - Siwei Xiong
AU - Ping Tang
PY - 2026
DA - 2026/10/29
JO - Cancer medicine
DO - 10.1002/cam4.72440
UR - https://europepmc.org/article/MED/42952419
AB - Background Prostate-specific antigen (PSA) and PSA density (PSAD) are widely used for prostate cancer (PCa) screening, but their diagnostic thresholds have not been differentially adjusted for ethnic groups in clinical practice. This multicenter study aimed to establish the distribution of PSA and PSAD in Chinese men without PCa and compare these values with published data from African American (AA) and Caucasian American (CA) men to assess potential racial disparities.Methods We analyzed 528 biopsy-negative Chinese men from two tertiary centers, comparing their age-adjusted PSA/PSAD with published AA/CA data. Additionally, we compared PSA/PSAD distributions and the proportion of men exceeding the conventional PSA cutoff (4 ng/mL) across racial groups.Results PSA levels showed a weak but significant positive correlation with age (r = 0.121, p = 0.005), whereas PSAD did not (r = -0.032, p = 0.465). Notably, Chinese men without PCa exhibited significantly higher mean PSA and PSAD than AA and CA men (PSA: 17.28 vs. 7.97 vs. 4.30 ng/mL, p < 0.001; PSAD: 0.28 vs. 0.19 vs. 0.11 ng/mL/mL, p < 0.001). Using a PSA cutoff of 4 ng/mL, the specificity for PCa detection was substantially lower in Chinese men than in AA and CA men at matched sensitivity levels.Conclusions This study reveals striking racial differences in baseline PSA and PSAD among men without PCa, with Chinese men demonstrating markedly higher values than AA and CA counterparts. These findings challenge the universal application of current PSA thresholds and underscore the need for race-specific adjustments to optimize PCa screening accuracy.
SN - 2045-7634
ER -